pharmaphorum4 天
MSD hits a hurdle with its LAG-3 programme
It's another setback for the LAG-3 category in MSS colorectal cancer, coming after Bristol-Myers Squibb's combination of PD-1 nivolumab and LAG-3 drug relatlimab – approved as Opdualag for ...
pharmaphorum3 天
Immutep mulls filings for LAG-3 drug after new readout
The first drug in the LAG-3 inhibitor class to reach the market was Bristol-Myers Squibb’s Opdualag, a fixed-dose combination of LAG-3 drug relatlimab with PD-1 inhibitor nivolumab, sold on its ...
American Association of Individual Investors3 天
Which Is a Better Investment, Amgen, Inc. or Bristol-Myers Squibb Co Stock?
It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory ...
American Association of Individual Investors5 天
Which Is a Better Investment, Bristol-Myers Squibb Co or Pfizer Inc. Stock?
It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory ...
科印网4 天
2025美国印刷买家TOP10预测榜单发布，超50%买家印刷需求下降！
日前，美国Printing Impressions杂志发布了2025年美国百强印刷买家榜单。2025年美国百强印刷买家的印刷需求预计为563.96亿美元 ...